Abstract 185: The burden of cardiorenal complications in type 2 diabetes (T2D) – Insights from the Take CaRe of Me India cohort

Background: Cardiorenal complications (CRCs) associated with T2D are a major cause of morbidity and mortality. There is a paucity of data regarding the burden of undiagnosed silent CRCs among individuals with T2D in India. Aim: To present country-specific analyses from the 'Take CaRe of Me' program, a subset of the iCaReMe global, cloud-based registry (NCT03549754), evaluating the prevalence and clinical manifestations of CRCs among individuals with T2D from the primary care setting in India. Methods: Cross-sectional data of adults with T2D and no history of CRCs at index visits were collected from December 2020 through December 2021. Here we present descriptive analyses of baseline cardiorenal characteristics. Presence of cardiovascular (CV) risk was analyzed as per ESC 2019 guidelines and renal risk as per KDIGO guidelines. Continuous variables were summarized as mean ± SD and categorical variables as frequency (%). Results: A total of 3284 individuals (mean ± SD age: 54.8 ± 11.92 years, BMI: 26.7 ± 4.7 kg/m2; 46.6% females) were enrolled. Mean HbA1c was 8.1 ± 1.97% (62.7% with HbA1c ≥7%) with a mean T2D duration of 9.1 ± 7.21 years; 61.5% of individuals had a T2D duration ≥5 years. Hypertension was reported in one-third (34.3%). Overall, 1091 (33.2%) individuals had moderate-to-severe renal risk (per urine albumin creatinine ratio). Of the 1280 (39.0%) individuals with high and very high CV risk, 251 (19.6%) had echocardiographic data, of whom, 70 (27.9%) had abnormal echocardiogram (12.0% left ventricular hypertrophy, 8.4% left atrial enlargement, 4.4% valvular disease, 2.4% diastolic dysfunction, and 0.8% pulmonary hypertension). Clinical heart failure was detected in 18 (0.5%) individuals overall [Table]. Conclusion: The results show silent CRCs to be prevalent in more than one-third of individuals with T2D. Such a high burden of unrecognized CRCs highlights the unmet need for early diagnosis, risk factor management, and the use of cardioreno protective anti-hyperglycemic drugs for individuals with long-standing T2D in India.